Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
The present invention provides heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines of Formula I: wherein X, Y, Z, L, A, R 5 , n, m, and r are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof; wherein:
X is CH or N;
Y is H, cyano, halo, C 1-3 alkyl, or C 1-3 haloalkyl;
Z is N;
L is O or S;
R 1 , R 2 , and R 3 are each independently H, hydroxy, halo, C 1-3 alkyl, or C 1-3 haloalkyl;
each R 5 is independently hydroxy, C 1-4 alkoxy, fluorine, C 1-4 alkyl, hydroxy-C 1-4 -alkyl, C 1-4 alkoxy-C 1-4 -alkyl, or C 1-4 fluoroalkyl;
A is C 1-6 alkyl, C 3-10 cycloalkyl, C 2-10 heterocycloalkyl, C 6-10 aryl, or C 1-10 heteroaryl; each optionally substituted with p independently selected R 7 substituents; wherein p is 1, 2, 3, 4, or 5;
each R 7 is independently selected from halo, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, C 1-10 heteroaryl, C 1-10 heteroaryl-C 1-4 -alkyl, —OR a , —SR a , —S(═O)R b , —S(═O) 2 b , —S(═O) 2 NR e R f , —C(═O)R b , —C(═O)OR a , —C(═O)NR e R f , —OC(═O)R b ,—OC(═O)NR e R f , —NR e R f , —NR c C(═O)R d , —NR c C(═O)OR d , —NR c C(═O)OR d , —NR c S(═O) 2 R d , and —NR c S(═O) 2 NR e R f ; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, C 1-10 heteroaryl, and C 1-10 heteroaryl-C 1-4 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R a , R c , R d , R e , and R f is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, C 1-10 heteroaryl, and C 1-10 heteroaryl-C 1-4 -alkyl; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, C 1-10 heteroaryl, and C 1-10 heteroaryl-C 1-4 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R b is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, C 1-10 heteroaryl, and C 1-10 heteroaryl-C 1-4 -alkyl; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, C 6-10 aryl, C 6-10 aryl-C 1-4 -alkyl, C 1-10 heteroaryl, and C 1-10 heteroaryl-C 1-4 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R g is independently selected from halo, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 -alkyl, C 2-7 heterocycloalkyl, C 2-7 heterocycloalkyl-C 1-3 -alkyl, phenyl, phenyl-C 1-3 -alkyl, C 1-7 heteroaryl, C 1-7 heteroaryl-C 1-3 -alkyl, —OR a1 , —SR a1 , —S(═O)R b1 , —S(═O) 2 R b1 , —S(═O) 2 NR e1 R f1 , —C(═O)R b1 , —C(═O)OR a1 , —C(═O)NR e1 R f1 , —OC(═O)R b1 , —OC(═O)NR e1 R f1 , —NR e1 R f1 , —NR c1 C(═O)R d1 , —NR c1 C(═O)OR d1 , —NR c1 C(═O)NR d1 , —NR c1 S(═O) 2 R d1 , and —NR c1 S(═O) 2 NR e1 R f1 ; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 -alkyl, C 2-7 heterocycloalkyl, C 2-7 heterocycloalkyl-C 1-3 -alkyl, phenyl, phenyl-C 1-3 -alkyl, C 1-7 heteroaryl, and C 1-7 heteroaryl-C 1-3 -alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R h groups;
each R a1 , R c1 , R d1 , R e1 , and R f1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 -alkyl, C 2-7 heterocycloalkyl, C 2-7 heterocycloalkyl-C 1-3 -alkyl, phenyl, phenyl-C 1-3 -alkyl, C 1-7 heteroaryl, and C 1-7 heteroaryl-C 1-3 -alkyl; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 -alkyl, C 2-7 heterocycloalkyl, C 2-7 heterocycloalkyl-C 1-3 -alkyl, phenyl, phenyl-C 1-3 -alkyl, C 1-7 heteroaryl, and C 1-7 heteroaryl-C 1-3 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups;
each R b1 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 -alkyl, C 2-7 heterocycloalkyl, C 2-7 heterocycloalkyl-C 1-3 -alkyl, phenyl, phenyl-C 1-3 -alkyl, C 1-7 heteroaryl, and C 1-7 heteroaryl-C 1-3 -alkyl; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 -alkyl, C 2-7 heterocycloalkyl, C 2-7 heterocycloalkyl-C 1-3 -alkyl, phenyl, phenyl-C 1-3 -alkyl, C 1-7 heteroaryl, and C 1-7 heteroaryl-C 1-3 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups;
each R h is independently selected from cyano, halo, hydroxy, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, amino, C 1-4 alkylamino, di-C 1-4 -alkylamino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 - alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino;
m is 0, 1, or 2;
n is 0, 1, 2, 3, or 4; and
r is 1, 2, or 3.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is N.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L is O.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is cyano.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , and R 3 are each H.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each R 5 is fluorine.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein r is 1.
10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is phenyl, a 5-membered heteroaryl ring, or a 6-membered heteroaryl ring; each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R 7 substituents.
11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein each R 7 is independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, —C(═O)R b , and —C(═O)NR e R f ; wherein said C 1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R g groups.
12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is N;
Z is N;
L is O;
R 1 , R 2 , and R 3 are each H;
each R 5 is fluorine;
A is C 3-10 cycloalkyl, C 2-10 heterocycloalkyl, C 6-10 aryl, or C 1-10 heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R 7 substituents;
each R 7 is independently selected from halo, cyano, nitro, C 1-6 alkyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl, —OR a , —SR a , —S(═O)R b , —S(═O) 2 R b , —S(═O) 2 NR e R f , —C(═O)R b , —C(═O)OR a , —C(═O)NR e R f , —OC(═O)R b , —OC(═O)NR e R f , —NR e R f , —NR c C(═O)R d , —NR c C(═O)OR d , —NR c C(═O)NR d , —NR c S(═O) 2 R d , and —NR c S(═O) 2 NR e R f ; wherein said C 1-6 alkyl, C 3-10 cycloalkyl, C 3-10 cycloalkyl-C 1-4 -alkyl, C 2-10 heterocycloalkyl, C 2-10 heterocycloalkyl-C 1-4 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R g is independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, C 2-7 heterocycloalkyl, —OR a1 , —S(═O) 2 R b1 , —S(═O) 2 NR e1 R f1 , —C(═O)R b1 , —C(═O)OR a1 , —C(═O)NR e1 R f1 , —OC(═O)R b1 , —OC(═O)NR e1 R f1 , —NR c1 C(═O)R d1 , —NR c1 C(═O)OR d1 , —NR c1 C(═O)NR d1 , —NR c1 S(═O) 2 R d1 , and —NR c1 S(═O) 2 NR e1 R f1 ; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R h groups;
each R a , R c , R d , and R e is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl, wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R b is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R f is independently selected from H and C 1-6 alkyl;
each R a1 , R c1 , R d1 , and R e1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups; and
each R b1 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl optionally substituted by 1, 2, 3, or 4 independently selected R h groups;
m is 1;
n is 0, 1, or 2; and
r is 1.
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is N;
Z is N;
L is O;
R 1 , R 2 , and R 3 are each H;
each R 5 is fluorine;
A is C 6-10 aryl or C 1-10 heteroaryl, each of which is optionally substituted with 1, 2, 3, 4, or 5 independently selected R 7 substituents;
each R 7 is independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, —OR a , —S(═O) 2 R b , —S(═O) 2 NR e R f , —C(═O)R b , —C(═O)OR a , and —C(═O)NR e R f ; wherein said C 1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R g is independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 2-7 heterocycloalkyl, —OR a1 , —C(═O)NR e1 R f1 , and —NR e1 R f1 ; wherein said C 1-6 alkyl and C 2-7 heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R h groups;
each R a and R c is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R b is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R f is independently selected from H and C 1-6 alkyl;
each R e1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl, wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups;
each R f1 is independently selected from H and C 1-6 alkyl;
m is 1;
n is 0, 1, or 2; and
r is 1.
14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is N;
Z is N;
L is O;
Y is cyano;
R 1 , R 2 , and R 3 are each H;
each R 5 is fluorine;
A is C 6-10 aryl, optionally substituted with 1, 2, 3, 4, or 5 independently selected R 7 substituents;
each R 7 is independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, —C(═O)R b , and —C(═O)NR e R f ; wherein said C 1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R g is independently selected from halo, cyano, C 1-6 alkyl, C 2-7 heterocycloalkyl, —C(═O)NR e1 R f1 , and —NR e1 R f1 ; wherein said C 1-6 alkyl and C 2-7 heterocycloalkyl is optionally substituted with 1 or 2 independently selected R h groups;
each R h is independently selected from halo, C 1-4 alkyl, and C 1-4 alkoxy;
each R e is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl, wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R f is independently selected from H and C 1-6 alkyl;
each R b is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R e1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl, wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups;
each R f is independently selected from H and C 1-6 alkyl;
m is 1;
n is 0 or 1; and
r is 1.
15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
X is N;
Z is N;
L is O;
Y is cyano;
R 1 , R 2 , and R 3 are each H;
each R 5 is fluorine;
A is phenyl, optionally substituted with 1, 2, 3, 4, or 5 independently selected R 7 substituents;
each R 7 is independently selected from halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, —C(═O) b , and —C(═O)NR e R f ; wherein said C 1-6 alkyl is optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R g is independently selected from halo, cyano, C 1-6 alkyl, C 2-7 heterocycloalkyl, —C(═O)NR e1 R f1 , and —NR e1 R f1 ; wherein said C 1-6 alkyl and C 2-7 heterocycloalkyl is optionally substituted with 1 or 2 independently selected R h groups;
each R h is independently selected from halo, C 1-4 alkyl, and C 1-4 alkoxy;
each R e is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl, wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R f is independently selected from H and C 1-6 alkyl;
each R b is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl; wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are optionally substituted by 1, 2, 3, or 4 independently selected R g groups;
each R e1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl, wherein said C 1-6 alkyl, C 3-7 cycloalkyl, and C 2-7 heterocycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups;
each R f1 is independently selected from H and C 1-6 alkyl;
m is 1;
n is 0 or 1; and
r is 1.
16. The compound of claim 1 , wherein said compound is a compound of Formula II:
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 , wherein said compound is a compound of Formula III:
or a pharmaceutically acceptable salt thereof.
18. A compound of claim 1 , selected from:
4-[4-(3,5 -difluorophenoxy)piperidin-1- yl]-3-[4-(7H-pyrrolo[2,3 -d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-[4-(3-chloro-5-fluorophenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-{4-[3-fluoro-5-(trifluoromethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-4-[4-(3,4,5-trifluorophenoxy)piperidin-1-yl]butanenitrile;
3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-4-[4-(2,3,5-trifluorophenoxy)piperidin-1-yl]butanenitrile;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluorobenzonitrile;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N-methylbenzamide;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N,N-dimethylbenzamide;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-N-ethyl-5-fluorobenzamide;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-N-cyclopropyl-5-fluorobenzamide;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N-isopropylbenzamide;
N-(2-cyanoethyl)-3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}peperidin-4-yl)oxy]-5-fluorobenzamide;
4-{4-[3-fluoro-5-(pyrrolidin-1-ylcarbonyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
N-(3-amino-3-oxopropyl)-3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl) oxy]-5-fluorobenzamide;
N-(tert-butyl)-3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluorobenzamide;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}piperidin-4-yl)oxy]-5-fluoro-N-(2-morpholin-4-ylethyl)benzamide;
4-{4-[3-fluoro-5-(piperidin-1-ylcarbonyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-{4-[3-fluoro-5-(morpholin-4-ylcarbonyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-(4-{3-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-[4-(3-{[cyclopropyl(methyl)amino]methyl}-5-fluorophenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-{4-[3-(azetidin-1-ylmethyl)-5-fluorophenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-(4-{3-[(cyclobutylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-{4-[3-fluoro-5-(pyrrolidin-1-ylmethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-{4-[3-fluoro-5-(piperidin-1-ylmethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-{4-[3-fluoro-5-(morpholin-4-ylmethyl)phenoxy]piperidin-1-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1H-pyrazol-1-yl]butanenitrile;
4-(4-{3-[(3,3-difluoropyrrolidin-1-yl)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-[4-(3-fluoro-5-{[2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-[4-(3-fluoro-5-{[(2-methoxyethyl)amino]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
3-[(1-{3-cyano-2-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propyl}-3-fluoropiperidin-4-yl)oxy]-5-fluorobenzonitrile; and
4-[3-fluoro-4-(3-fluoro-5-{[2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
or a pharmaceutically salt of any of the aforementioned.
19. A compound of claim 1 , selected from:
4-[4-(3-fluoro-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-[4-(3-fluoro-5-{[(2S)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
4-[3-fluoro-4-(3-fluoro-5-{[(2R)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile; and
4-[3-fluoro-4-(3-fluoro-5-{[(2S)-2-methylpyrrolidin-1-yl]methyl}phenoxy)piperidin-1-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile;
or a pharmaceutically salt of any of the aforementioned.
20. The compound according to claim 1 , wherein the compound is the (R)-enantiomer, or a pharmaceutically acceptable salt thereof.
21. The compound according to claim 1 , wherein the compound is the (S)-enantiomer, or a pharmaceutically acceptable salt thereof.
22. A composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
23. A method of inhibiting an activity of JAK1 comprising contacting JAK1 with a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
24. A method according to claim 23 , wherein said compound, or pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2.
25. A method of treating rheumatoid arthritis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
26. A method of treating psoriasis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.
27. A method of treating lymphoma, leukemia, or multiple myeloma in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
28. A method of treating polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
29. A method of treating myelofibrosis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
30. A method of treating primary myelofibrosis (PMF) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
31. A method of treating organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
32. A method of treating polycythemia vera (PV) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
33. A method of treating essential thrombocythemia (ET) in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
34. A compound which is 4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.
35. The compound of claim 34 , where the compound is (R)-4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.
36. The compound of claim 34 , which is (S)-4-(4-{3-[(dimethylamino)methyl]-5-fluorophenoxy}piperidin-1-yl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile, or a pharmaceutically acceptable salt thereof.